MAPT and Alzheimer disease: Although this is far less compared to the 5 years’ doubling time of aggregated tau that we previously determined in the brain of AD patients,14 it should be noted that the slower replication rates in vivo might be a result of supportive clearance mechanisms for toxic by-products.52,53